A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)

Trial Profile

A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Cenicriviroc (Primary) ; Famotidine; Omeprazole
  • Indications Cancer; Diabetic neuropathies; Graft-versus-host disease; HIV-1 infections; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
  • Focus Pharmacokinetics
  • Sponsors Tobira Therapeutics
  • Most Recent Events

    • 21 Nov 2017 Status changed from active, no longer recruiting to completed.
    • 18 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 20 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top